Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06714942 · ClinicalTrials.gov registry record · NA

Efficacy and Safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women With High Stress and Anxiety: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study

A NA study of Anxiety and Stress, sponsored by SF Research Institute.

Recruiting
Registry status
NA
Development phase
51
Enrollment target
1
Study location

NCT06714942: Recruiting NA study of Anxiety and Stress, sponsored by SF Research Institute.

NCT06714942 is a NA study of Anxiety and Stress that is actively recruiting participants, run by SF Research Institute. The registered enrollment target is 51 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06714942, a NA study of Anxiety and Stress, is actively recruiting participants, sponsored by SF Research Institute.

RECRUITING
Registry status
NA
Development phase
51 participants
Enrollment target
1
Study location

Study Summary

This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women with High Stress and Anxiety. All eligible subjects who meet the Inclusion and Exclusion criteria will be part of the study. Subjects will be informed about the purpose of the study and signed informed consent will be taken. Subjects will be randomized to either one of the three treatment arms. Subjects will then be asked to either take one capsule containing the proprietary blend of Ashwagandha root extract or Ashwagandha root extract or Placebo orally twice daily with a glass of water for 8 weeks. The primary objective is to compare the efficacy of a proprietary blend of Ashwagandha root extract in adults experiencing stress and anxiety. The secondary objective is to compare the safety of a proprietary blend versus KSM-66 versus Placebo in adults experiencing stress and anxiety.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Proprietary Blend of Ashwagandha
  • DIETARY_SUPPLEMENT KSM-66 Ashwagandha root extract

Study Locations (1)

California

  • San Francisco Research Institute - San Francisco

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2024-10-25
Est. Completion 2025-01-21
Phase NA
SF Research Institute

16 total trials

What NCT06714942 shows while recruiting

NCT06714942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06714942 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06714942 about?

NCT06714942 is a clinical study titled "Efficacy and Safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women With High Stress and Anxiety: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study". This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women with High Stress and Anxiety. All eligible subjects who meet the ...

What is the current status of trial NCT06714942?

This trial is currently recruiting. It is a NA study. The enrollment target is 51 participants. The study started on 2024-10-25. Estimated completion is 2025-01-21.

What conditions does trial NCT06714942 study?

This clinical trial studies the following conditions: Anxiety, Stress.

What interventions are being tested in trial NCT06714942?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Proprietary Blend of Ashwagandha (DIETARY_SUPPLEMENT), KSM-66 Ashwagandha root extract (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06714942?

This trial is sponsored by SF Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06714942 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06714942's enrollment target sits among peer trials

51 244th of 364 higher than 120 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06714942, the US trial registry maintained by the National Library of Medicine. NCT06714942 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.